Back to Search Start Over

KRASsignalling in malignant pleural mesothelioma

Authors :
Michael Lindner
Marianthi Iliopoulou
Mario A.A. Pepe
Ina Koch
Sophia G. Antimisiaris
Marc Grégoire
I Psallidas
Rudolf Hatz
Ioannis Lilis
Anthi C. Krontira
M Spella
Darcy E. Wagner
Georgios T. Stathopoulos
C. M. Hackl
A. Marazioti
Ioanna Giopanou
Helen Papadaki
S. Deshayes
Malamati Vreka
Christophe Blanquart
Juergen Behr
Anne-Sophie Lamort
Publication Year :
2020
Publisher :
Cold Spring Harbor Laboratory, 2020.

Abstract

Malignant pleural mesothelioma (MPM) arises from mesothelial cells lining the pleural cavity of asbestos-exposed individuals and rapidly leads to the development of pleural effusion and death. MPM harbours loss-of-function mutations in genes likeBAP1, NF2, CDKN2A, andTP53, but isolated deletion of these genes alone in mice does not cause MPM and mouse models of the disease are sparse. Here we show that a significant proportion of human MPM harbour point mutations and copy number alterations in theKRASproto-oncogene. These mutations are likely pathogenic, since ectopic expression of mutantKRASG12Din the pleural mesothelium of conditional mice causes MPM. Murine MPM cell lines derived from these tumours carry the initiatingKRASG12Dlesions, secondaryBap1alterations, and human MPM-like gene expression profiles. Moreover, they are transplantable and actionable by KRAS inhibition. Our results indicate thatKRASmutations likely play an important and underestimated role in MPM, which warrants further exploration.

Details

Database :
OpenAIRE
Accession number :
edsair.doi...........474f28a1fa8aea25ba88ee8975f0562f